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Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) are a popular
chemogenetic technology for manipulation of neuronal activity in uninstrumented awake
animals with potential for human applications as well. The prototypical DREADD agonist
clozapine N-oxide (CNO) lacks brain entry and converts to clozapine, making it difﬁcult to
apply in basic and translational applications. Here we report the development of two novel
DREADD agonists, JHU37152 and JHU37160, and the ﬁrst dedicated 18F positron emission
tomography (PET) DREADD radiotracer, [18F]JHU37107. We show that JHU37152 and
JHU37160 exhibit high in vivo DREADD potency. [18F]JHU37107 combined with PET allows
for DREADD detection in locally-targeted neurons, and at their long-range projections,
enabling noninvasive and longitudinal neuronal projection mapping.
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Designer receptors exclusively activated by designer drugs(DREADD)1 technology is a powerful chemogeneticapproach used for neuromodulation in uninstrumented
research animals. Combining a DREADD with translational
molecular imaging methods such as positron emission tomo-
graphy (PET) could extend this technique to clinical applications,
by providing a means for noninvasive conﬁrmation of receptor
expression and function. DREADD ligands developed to date
have characteristics that limit their utility for translational central
nervous system (CNS) applications2. The prototypical DREADD
agonist, clozapine N-oxide (CNO), has poor brain penetrance
and, via metabolic degradation, gives rise to the antipsychotic
drug clozapine, which is the main active in vivo CNS DREADD
agonist2. Therefore new, potent DREADD agonists and selective,
high-afﬁnity DREADD PET radioligands are needed to advance
the translational potential of this powerful chemogenetic tech-
nology. Here, we use an array of complementary in vitro, ex vivo
and in vivo approaches in rodents and in monkeys to report the
development of JHU37152 and JHU37160, the ﬁrst DREADD
agonists with high in vivo potency for CNS applications. We also
report the development of the ﬁrst 18F-labeled high-afﬁnity
DREADD PET radioligand, [18F]JHU37107, which enables
noninvasive and longitudinal DREADD detection and localiza-
tion in locally targeted neurons and at long-range projection sites.
Together, these new tools expand the power of DREADD che-
mogenetic technology to encompass translational applications for
noninvasive manipulation and visualization of neuronal circuits.
Results
New DREADD ligands with high in vitro afﬁnity and potency.
Recently, a new second-generation DREADD ligand, Compound
21 (C21), was put forward as an effective DREADD agonist with
excellent brain penetrance that does not convert to clozapine3–5.
However, there have not yet been reports of the use of C21 in
nonhuman primates (NHP). To determine the extent to which
C21 is suitable for activating DREADDs, we carried out a com-
prehensive series of studies in rodents and rhesus monkeys
described in Supplementary Figs. 1 and 2. Collectively, our
ﬁndings suggest that C21, like CNO, exhibits lower in vivo
DREADD potency than clozapine and is particularly not efﬁcient
in NHP applications.
To search for potent DREADD agonists suitable for in vivo
biological studies, we would like to identify new ligands with good
performance. To this end, we proﬁled two other compounds from
the series described by Chen et al.3. Compound 13 (C13)
and Compound 22 (C22) (Fig. 1a). Both C13 and C22 exhibited
high-DREADD afﬁnity and C13 had twofold higher afﬁnity
(hM3DqKi= 4.3 nM; hM4DiKi= 4.3 nM) than C22 (hM3DqKi=
11 nM; hM4DiKi= 9 nM) (Fig. 1b). Correspondingly with its
binding afﬁnity, C13 (10 nM) was able to displace [3H]clozapine
selectively from hM3Dq but not from endogenous clozapine-
binding sites (Fig. 1c, d). Next, we synthesized [3H]C13, which
bound DREADDs expressed in brain tissue sections at very low
concentrations, exhibited greater DREADD selectivity than [3H]
clozapine (particularly in the macaque) (Fig. 1e–h) and a
promising peripheral biodistribution proﬁle in mice (Supplemen-
tary Fig. 3). [3H]C13 exhibited high ex vivo DREADD
engagement in dopamine D1 receptor (D1)-DREADD mice
(Fig. 1i) indicating high brain bioavailability and direct DREADD
engagement.
The PET radioligand [11C]clozapine has been used to image
DREADDs in vivo in rodents and in NHPs2,6,7. However, the
short half-life (~20min) of the 11C radionuclide does not permit
combined use of chemogenetics with PET at institutions that lack
cyclotrons and thus limits its overall research and potential clinical
use. The 18F radionuclide, with a half-life of ~110 min, allows for
commercialization, extends the use of PET to chemogenetics
applications at institutions that lack cyclotrons, and facilitates
imaging at longer time intervals. To make an 18F-labeled PET
DREADD ligand, we designed and synthesized ﬂuorinated
analogs of C13 and C22. We reasoned that the presence of the
additional ﬂuorine would make it simple to radiolabel the
compound with 18F via direct substitution, and by exploring
various potential sites for ﬂuorination we would be able to
preserve, or perhaps even improve DREADD afﬁnity. We
identiﬁed three analogs, JHU37107 (hM3DqKi= 10.5 nM;
hM4DiKi= 23.5 nM), JHU37152 (hM3DqKi= 1.8 nM; hM4DiKi=
8.7 nM), and JHU37160 (hM3DqKi= 1.9 nM; hM4DiKi= 3.6 nM)
displaying the highest in vitro DREADD afﬁnity (Fig. 1j–l). We
then docked the highest-afﬁnity JHU37160 in the ligand binding
pocket of an hM4Di model and identiﬁed a stable pose of
JHU37160 using molecular dynamics simulations (Fig. 1m). In
the selected pose, the pyramidal nitrogen of JHU37160 forms an
ionic interaction with Asp1123.32, and its ethyl group makes
favorable hydrophobic-aromatic interactions with Tyr416,
Tyr439, and Tyr443, which likely contribute to the ~25-fold
improved afﬁnity of JHU37160 compared to C21. The chloride
group of JHU37160 forms a halogen bond with the backbone
carbonyl oxygen of Gly203 (note Gly203 is one of the two
mutations in DREADD). Based on this pose, we predicted that
ﬂuorination at the para positions would be well tolerated, which
was indeed the case for JHU37152 and JHU37160.
We tested both compounds for in situ [3H]clozapine displace-
ment in brain tissue from WT and D1-DREADD mice and found
that both JHU37152 and JHU37160 exhibited selective [3H]
clozapine displacement from DREADDs and not from other
clozapine-binding sites at concentrations up to 10 nM (Fig. 1n, o).
In addition, both compounds were potent DREADD agonists
with high potency and efﬁcacy in ﬂuorescent and BRET-based
assays in HEK-293 cells; JHU37152: (hM3DqEC50: 5 nM;
hM4DiEC50: 0.5 nM) and JHU37160: (hM3DqEC50: 18.5 nM;
hM4DiEC50: 0.2 nM) (Fig. 1p, q), whereas no responses were
observed in untransfected HEK-293 cells (Supplementary Fig. 4).
JHU37152 and JHU37160 exhibit high in vivo DREADD
occupancy. In contrast to CNO and C21, mice injected (IP) with
a 0.1 mg kg−1 dose of either JHU37152 or JHU37160 (Fig. 2a)
showed high brain to serum concentration ratios (~eightfold
higher in the brain than serum at 30 min), indicating active
sequestration in brain tissue (Fig. 2b). Neither JHU37152 nor
JHU37160 were P-gp substrates (Supplementary Fig. 5). The CSF
concentration of JHU37160 at this same dose in the monkey was
below our system’s detection limit. However, JHU37160 was
detected in serum where it showed a similar proﬁle as in the
mouse (Supplementary Fig. 6). At this same dose, 0.1 mg kg−1,
JHU37152 and JHU37160 occupied approximately 15–20% of
striatal DREADDs in mice (Fig. 2c, d). In rats, 0.1 mg kg−1
JHU37160 occupied approximately 80% of cortical hM4Di
(Fig. 2e, f). In monkey, 0.1 mg kg−1 JHU37160 (and to a lesser
extent, 0.01 mg kg−1) produced [11C]clozapine DREADD dis-
placement at hM4Di expressed in the amygdala (Fig. 2g, h, and
Supplementary Fig. 6).
JHU37152 and JHU37160 exhibit high in vivo DREADD
potency. As predicted from the above ﬁndings, JHU37152 and
JHU37160 were potent in vivo DREADD agonists, selectively
inhibiting locomotor activity in D1-hM3Dq and D1-hM4Di mice
at doses ranging from 0.01 to 1 mg kg−1 without any signiﬁcant
locomotor effects observed at these doses in WT mice (Fig. 3a–c).
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Fig. 1 New DREADD ligands displaying high in vitro DREADD afﬁnity and potency. a Compound 13 (C13) and Compound 22 (C22) structures. b Binding
competition curves of [3H]CLZ versus increasing concentrations of C13 and C22 in HEK-293 cells expressing DREADDs. C13 and C22 exhibit comparable
DREADD afﬁnity to clozapine (CLZ) with C13 showing ~twofold greater afﬁnity than C22. CLZ and C21 competition curves from Supplementary Fig. 1 are
overlaid for comparison. c, d C13 selectively blocks [3H]CLZ binding to DREADDs in mouse slices at 10 nM. Representative images of sections collected
from 3 different mice are displayed and quantiﬁed in (d) as mean ± SEM. Two-way ANOVA followed by Dunnett’s test, *p < 0.05 and **p < 0.01 compared
with the respective vehicle. e–h [3H]C13 binds with greater selectivity than [3H]CLZ to DREADDs in mouse and monkey brain tissue expressing AAV-
hM3Dq and AAV-hM4Di, respectively. i Intraperitoneal (IP) injection of [3H]C13 readily enters the brain and accumulates in DREADDs expression areas in
D1-DREADD mice. Representative images from 3 mice per condition. j–l JHU37107 (J07), JHU37152 (J52), and JHU37160 (J60) are high-afﬁnity DREADD
ligands.m Docking and molecular dynamics simulation of J60 in the ligand binding pocket of a hM4Di model. n, o J60 and J52 selectively displace [3H]CLZ
at a concentration of 1 and 10 nM from hM3Dq and hM4Di expressed in mouse brain sections (n= 3 mice per condition). p, q J60 and J52 activate hM3Dq
and hM4Di expressed in HEK293 cells with high potency (experiments performed 3–5 times). In all cases, data are represented as mean ± SEM. Scale bars
are 1 mm. Source data are provided as a Source Data ﬁle
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Fig. 2 JHU37152 and JHU37160 exhibit high in vivo DREADD occupancy. a Structures of JHU37152 (J52) and JHU37160 (J60). b Brain and serum
concentrations and ratios of J52 and J60 in mice (n= 4 mice per condition) at different time points after a 0.1 mg kg−1 (IP) injection. C21 (1 mg kg−1, IP)
data are same as shown in Supplementary Figures for comparison purposes. c, d J52 and J60 (0.1 mg kg−1, IP) displace in vivo [11C]clozapine binding to
DREADDs in AAV-DREADD-expressing mice (n= 5 mice). e, f J60 (0.1 mg kg−1, IP) selectively blocks in vivo [11C]clozapine binding to DREADDs in rats
(n= 3 rats). g, h J60 (0.1 mg kg−1) blocks in vivo [11C]clozapine binding to hM4Di in the monkey. All data represented are mean ± SEM except in (h) where
individual values are displayed. Source data are provided as a Source Data ﬁle
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Fig. 3 JHU37152 and JHU37160 exhibit high in vivo DREADD potency. a–c J60 and J52 produce potent inhibition of locomotor activity in transgenic D1-
DREADD mice but not in wild-type (WT) mice (n= 7 to 19 mice per condition). Two-way repeated measures ANOVA followed by Dunnett’s multiple
comparison tests were performed, *p < 0.05 and **p < 0.01 compared with the respective vehicle. d, e DREADD-assisted metabolic mapping (DREAMM)
using [18F]FDG in D1-hM3Dq and D1-hM4Di mice (n= 4 mice per condition) reveals opposing and differential recruitment of whole-brain functional
networks. f, g J52 and J60 produce potent activation of locomotor activity in rats (n= 7 rats per condition) expressing hM3Dq in tyrosine
hydroxylase (TH)-expressing neurons in the ventral tegmental area. One-way repeated measures ANOVA followed by Dunnett’s multiple comparison
tests were performed, *p < 0.05 and **p < 0.01 compared with the respective vehicle. h–j Design of in vivo electrophysiological experiment and IHC showing
hM4Di (green) and ChrimsonR (red) expression in the medial division of the medial geniculate nucleus (MGM) and lateral amygdala (LA). k, l J60
(0.1 mg kg−1) produces rapid and potent hM4Di-driven inhibition of light-evoked neuronal activation. Data are represented as mean ± SEM, *p < 0.05,
***p < 0.001. Source data are provided as a Source Data ﬁle
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Using DREADD-assisted metabolic mapping (DREAMM)8,9
with the [18F]ﬂuorodeoxyglucose (FDG) tracer to assess changes
in regional brain activity after hM3Dq or hM4Di activation of D1
neurons, 0.1 mg kg−1 (IP) JHU37160 produced metabolic
changes in distinct and largely nonoverlapping brain networks
in D1-hM3Dq (Fig. 3d) versus D1-hM4Di (Fig. 3e) mice and
caused no signiﬁcant brain metabolic changes in WT mice
(Supplementary Fig. 7). The recruitment of distinct, almost
mutually exclusive networks was paralleled by metabolic changes
with opposite directionality upon differential modulation of D1
neurons with hM3Dq and hM4Di: decreased metabolism in D1-
hM3Dq and increased metabolism in D1-hM4Di mice, effects
likely mediated via activation and inhibition of striatal GABAer-
gic D1-expressing neurons respectively.
In a competitive binding screen, JHU37152 and JHU37160
exhibited lower afﬁnity than clozapine at 5-HT receptors
(Supplementary Fig. 8). Although the overall target proﬁle of
both compounds was similar to clozapine, they did not produce
any agonistic effect in functional assays performed in HEK-293
cells lacking DREADDs, but expressing endogenous clozapine-
binding targets10 (Supplementary Fig. 4). As such, they are
expected to behave as antagonists at these receptors, competing
with endogenous neurotransmitters at these same binding sites.
In contrast, JHU37152 and JHU37160 evidenced DREADD
activation at lower concentrations than clozapine, indicating that
the former compounds are more selective DREADD agonists.
In TH-hM3Dq rats, 0.01–0.3 mg kg−1 JHU37152 and
JHU37160 led to robust, selective increases in hM3Dq-
stimulated locomotion (Fig. 3f, g). To further characterize the
performance of JHU37160 as an in vivo DREADD agonist, we
performed in vivo electrophysiology experiments in which
hM4Di was co-expressed with a new light-drivable channelrho-
dopsin, ChrimsonR (Supplementary Fig. 9), in the terminals of
the medial division of the medial geniculate nucleus (MGM) to
striatum/lateral amygdala (LA) pathway (Fig. 3h–j) in mice. Mice
were implanted with optrodes in the LA. A dose of 0.1 mg kg−1
(IP) JHU37160 elicited rapid inhibition of ChrimsonR-induced
terminal activation; 60% inhibition was observed at ~10 min (36
± 9% of baseline), and maximal inhibition at 30 min after
injection (19 ± 2% of baseline) (Fig. 3k, l). These effects were
hM4Di-dependent; the same injection of JHU37160 had no effect
on electrical stimulation evoked responses in animals without
DREADD expression (Supplementary Fig. 10).
[18F]JHU37107 enables noninvasive neuronal projection
mapping. The high-afﬁnity proﬁles of JHU37152, JHU37160, and
JHU37107 stimulated efforts to develop them into 18F-labeled
PET imaging probes. Unfortunately, the discrete positions of the
ﬂuorine atoms in JHU37152 and JHU37160 made radiosynthesis
efforts challenging and inefﬁcient. The most radiochemically
favorable structure was [18F]JHU37107 which we radiolabeled
with high yield, molar activity and radiochemical purity (Fig. 4a).
In D1-DREADD transgenic mice, [18F]JHU37107 exhibited
robust uptake in DREADD-expressing brain regions as compared
to areas devoid of DREADD expression (Fig. 4b–d). This signal
was displaceable by 0.1 mg kg−1 (IP) JHU37160 (Fig. 4b–d)
indicating speciﬁc binding of [18F]JHU37107 at DREADD sites.
We also tested [18F]JHU37107 in rats with unilateral hM3Dq
(Fig. 4e) or hM4Di (Fig. 4f–j) expression in the right motor
cortex. [18F]JHU37107 permitted hM4Di visualization in both the
AAV injection site as well as at known proximal and distal
anatomical projection sites such as striatum, contralateral cortex,
and motor thalamus. The in vivo localization of the [18F]
JHU37107 signal matched the ex vivo expression of DREADDs
established by post hoc immunohistochemistry staining
(Fig. 4f–j). Finally, we tested [18F]JHU37107 in a monkey
expressing hM4Di in the right amygdala (Fig. 4k). [18F]
JHU37107 exhibited favorable pharmacokinetic properties
(Fig. 4l, m) and metabolite proﬁle (Supplementary Fig. 11) in this
species. More importantly, it was able to directly label hM4Di
receptors (Fig. 4k–m), allowing robust detection of DREADDs
with a dedicated 18F-labeled radioligand for the ﬁrst time in
nonhuman primates.
Discussion
The human muscarinic receptor-based DREADDs are the most
popular chemogenetic technology for basic research and are used
by a large number of laboratories around the world. Although the
majority of DREADD use has been in rodents, DREADDs have
also been applied for experimental use in monkeys recently6,11–13,
a critical step before human translation. Results from prior
studies2,5,14, and now from the current study, indicate that the
DREADD agonists developed to date, while efﬁcacious in certain
applications, do not display sufﬁcient potency or selectivity in
others. In rodents (rats and mice), we show here that C21 acti-
vated hM3Dq at doses as low as 0.1 mg kg−1, however, it was less
potent at activating hM4Di, which required at least 1 mg kg−1. In
mice without DREADDs, doses higher than 1 mg kg−1 produced
off-target effects. Furthermore, in WT mice, the 1 mg kg−1 dose
of C21 required to activate hM4Di produced changes in brain
metabolic activity (FDG uptake) even though we and others5 did
not detect any behavioral effects using this dose. In contrast, an
equipotent dose of clozapine (0.1 mg kg−1) did not produce any
signiﬁcant changes in brain metabolic activity. In monkeys, the
minimal doses required to achieve DREADD occupancy also
extensively displaced [11C]clozapine from endogenous targets
and produced nonspeciﬁc effects11. In summary, C21 has a small
window of selectivity to activate hM4Di in rodents, which may
potentially be compensated by overexpression of the DREADD
receptor, and furthermore displays a wide range of off-target
effects at the minimal hM4Di-effective doses in monkeys.
In addition to the characterization of C21, here we report the
development of a new set of DREADD agonists that exhibit high
in vivo potency and CNS DREADD occupancy in both rodents
and in old world monkeys. While their selectivity is not ideal (i.e.,
comparable to clozapine), their high in vivo potency allows for
dose adjustments with minimal off-target effects and importantly
they exhibit promising characteristics for DREADD use in
monkeys. Our data suggest that further steps to improve selec-
tivity require divergence from the dibenzodiazepine (clozapine-
based) scaffold and/or require new rationally engineered muta-
tions in the DREADD binding pocket to differentiate it from
endogenous wild-type receptors.
The other notable advance in this study is the development of
the ﬁrst, high-afﬁnity 18F-labeled DREADD PET ligand. The use
of 18F, with six times longer half-life than 11C, allows for this
ligand to be shipped to facilities without cyclotrons or that lack
the necessary radiosynthesis infrastructure and capabilities.
Moreover, it offers the possibility to scan several animals using
one synthesis or to perform longer scans for extensive kinetic
modeling and occupancy studies. Finally, this new PET ligand
provides strong somatic signaling of receptor expression in both
rodents and monkeys, and in rodents, at least, there is signal that
represents projections to remote locations from the primary viral
injection site, making noninvasive and longitudinal visualization
of cell type-speciﬁc neuroanatomical projections possible in the
living mammalian subject.
Chemogenetic technologies, like DREADDs confer the ability
to manipulate neuronal activity across distributed brain circuits
without the need for implantable devices15, thereby making them
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Fig. 4 [18F]JHU37107 enables noninvasive detection of DREADD in locally-targeted cells and at their long-range projections. a Structure of [18F]JHU37107.
b–d [18F]JHU37107 selectively binds to DREADDs in the brain of transgenic D1-DREADD mice (n= 3 mice per condition) and is blocked by 0.1 mg kg−1 of
JHU37160. e–j [18F]JHU37107 selectively binds to AAV-DREADDs expressed in the rat cortex and enables noninvasive and longitudinal mapping of both
local (injection site) and long-range projections of motor cortex circuitry (ventrolateral thalamus shown as a main hub). Representative
immunohistochemical images showing GFP (green) or HA-tagged DREADDs (red) from representative rats are shown side by side with their
corresponding [18F]JHU37107 PET images. The white arrows point at corresponding anatomical regions. k–m [18F]JHU37107 binds to hM4Di expressed in
the monkey amygdala and at putative projection sites. All data are represented as mean ± SEM except in (l) and (m) where individual values are displayed.
Scale bars are 1 mm. Source data are provided as a Source Data ﬁle and the raw PET data are available upon request
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especially useful in awake and even unrestrained animals. The
development of [18F]JHU37107 and our new agonists provide
means to perform diagnostic imaging of DREADDs in neu-
rotherapeutic contexts,—i.e., “neurotheranostics”16, making it
possible to imagine future development of cell type- and circuit-
speciﬁc neuromodulation for humans. In the same manner, since
FDG-PET is a routine human procedure, DREAMM8,9 can also
be used to evaluate, longitudinal, noninvasive assessment of
whole-brain, functional circuit activity as a function of
chemogenetic-based therapies. In sum, if the novel pharmacolo-
gical tools and approaches we describe here are extended to
humans, DREADD-based neurotheranostics16 would comprise a
novel precision-medicine approach that could be used for
developing chemogenetic-based cell type- and circuit-speciﬁc
neuromodulation for the precision or personalized treatment of
various brain disorders.
Methods
Experimental subjects. Wild-type mice (C57BL/6J) were ordered from Jackson
Laboratories and rats (Sprague–Dawley) were ordered from Charles River. Rodents
were male and ordered at ~6 weeks of age. Transgenic mice were bred at NIDA
breeding facility. Transgenic mice expressing the enzyme cre recombinase under
the control of the dopamine D1 receptor promoter (D1-Cre, FK150 line, C57BL/6J
congenic, Gensat, RRID: MMRRC_036916-UCD) were crossed with transgenic
mice with cre recombinase-inducible expression of hM4Di DREADD (R26-
hM4Di/mCitrine, Jackson Laboratory, stock no. 026219) or hM3Dq DREADD
(R26-hM3Dq/mCitrine, Jackson Laboratory, stock no. 026220). Three male rhesus
monkeys (Macaca mulatta) weighed 8–12 kg. All experiments and procedures
complied with all relevant ethical regulations for animal testing and research and
followed NIH guidelines and were approved by each institute’s animal care and use
committees.
Cell culture and transfection. Human embryonic kidney (HEK-293, ATCC) cells
were grown in Dulbecco’s modiﬁed Eagle’s medium (DMEM; Gibco, Thermo-
Fisher Scientiﬁc, Waltham, MA, USA) supplemented with 2 mM L-glutamine,
antibiotic/antimycotic (all supplements from Gibco) and 10% heat-inactivated fetal
bovine serum (Atlanta Biologicals, Inc. Flowery Branch, GA, USA) and kept in an
incubator at 37 °C and 5% CO2. Cells were routinely tested for myclopasma con-
tamination (MycoAlert® Mycoplasma Detection Kit, Lonza). Cells were seeded on
60 cm2 dishes at 4 × 106 cells/dish 24 h before transfection. The indicated amount
of cDNA was transfected into HEK-293 cells using polyethylenimine (PEI; Sigma-
Aldrich) in a 1–2 DNA:PEI ratio. Cell harvesting for radioligand binding experi-
ments or signaling assays were performed approximately 48 h after transfection.
Radioligand binding assays. HEK-293 cells were transfected with 5 µg/dish of
AAV packaging plasmids encoding for hM3Dq (Addgene #89149), hM4Di
(Addgene #89150) or a control vector and harvested 48 h after transfection. Cells
were suspended in Tris-HCl 50 mM pH 7.4 supplemented with protease inhibitor
cocktail (1:100, Sigma-Aldrich, St. Louis, MO, USA). The dissected brain tissue was
diluted in Tris-HCl 50 mM buffer supplemented with protease inhibitor cocktail
(1:1000). HEK-293 cells or brain tissue were disrupted with a Polytron homo-
genizer (Kinematica, Basel, Switzerland). Homogenates were centrifuged at 48,000g
(50 min, 4 °C) and washed twice in the same conditions to isolate the membrane
fraction. Protein was quantiﬁed by the bicinchoninic acid method (Pierce). For
competition experiments, membrane suspensions (50 µg of protein/ml) were
incubated in 50 mM Tris-HCl (pH 7.4) containing 10 mM MgCl2, 2.5 nM of [3H]
clozapine (83 Ci mmol−1, Novandi Chemistry AB, Södertälje, Sweden) and
increasing concentrations of the competing drugs during 2 h at RT. Nonspeciﬁc
binding was determined in the presence of 10 µM clozapine. In all cases, free and
membrane-bound radioligand were separated by rapid ﬁltration of 500-μl aliquots
in a 96-well plate harvester (Brandel, Gaithersburg, MD, USA) and washed with 2
ml of ice-cold Tris-HCl buffer. Microscint-20 scintillation liquid (65 μl/well, Per-
kinElmer) was added to the ﬁlter plates, plates were incubated overnight at RT and
radioactivity counts were determined in a MicroBeta2 plate counter (PerkinElmer,
Boston, MA, USA) with an efﬁciency of 41%. One-site competition curves were
ﬁtted using Prism 7 (GraphPad Software, La Jolla, CA, USA). Ki values were
calculated using the Cheng–Prusoff equation.
In vitro functional assays. BRET assays were performed to detect receptor ligand-
induced Gαo1 protein activation. HEK-293 cells were transfected with 5 µg/dish of
pAAV plasmids encoding for hM3Dq (Addgene #89149), hM4Di (Addgene
#89150) or a control vector together with 0.5 µg Gα-Rluc8, 4.5 µg β1 and 5 µg γ2-
mVenus/dish. Forty-eight hour after transfection cells were harvested, washed and
resuspended in phosphate-buffered saline (PBS). Approximately, 200,000 cells/well
were distributed in 96-well plates, and 5 µM Coelenterazine H (substrate for
luciferase) was added to each well. Five minutes after addition of Coelenterazine H,
ligands were added to each well. The ﬂuorescence of the acceptor was quantiﬁed
(excitation at 500 nm and emission at 540 nm for 1-s recordings) in a PheraStar
FSX plate reader (BMG Labtech) to conﬁrm the constant expression levels across
experiments. In parallel, the BRET signal from the same batch of cells was
determined as the ratio of the light emitted by mVenus (510–540 nm) over that
emitted by RLuc (485 nm). Results were calculated for the BRET change (BRET
ratio for the corresponding drug minus BRET ratio in the absence of the drug) 5
min after the addition of the ligands.
Intracellular Ca2+ concentration was monitored using the ﬂuorescent Ca2+
biosensor GCaMP6f. HEK-293 cells were transfected with 7 µg/dish of the cDNA
encoding for hM3Dq (Addgene #89149) or hM4Di (Addgene #89150) and 7 µg/
dish of GCaMP6. Forty-eight hours after transfection, cells were harvested, washed,
resuspended in Mg2+-free Locke’s buffer pH 7.4 (154 mM NaCl, 5.6 mM KCl, 3.6
mM NaHCO3, 2.3 mM CaCl2, and 5 mM HEPES) containing 5.6 mM of glucose
and approximately 200,000 cells/well were distributed in black 96-well plates.
Increasing concentrations of the indicated compound were added to the cells and
ﬂuorescence intensity (excitation at 480 nM, emission at 530 nM) was measured at
18-s intervals during 250 s using a PHERAstar FSX (BMG Labtech). The net
change in intracellular Ca2+ concentration was expressed as F− F0 where F is the
ﬂuorescence at a given concentration of ligand and F0 is the average of the baseline
values (ﬂuorescence values of buffer-treated wells).
Autoradiography. Flash frozen tissue (both rodents and the monkey) was sec-
tioned (20 µm) on a cryostat (Leica, Germany) and thaw mounted onto ethanol-
washed glass slides. Slides were pre-incubated (10 min, RT) in incubation buffer
(50 mM Tris-HCl pH 7.4 with 10 mM of MgCl2), then slides were incubated (60
min) in incubation buffer containing [3H]clozapine (3.5 nM), [3H]C21 (10 nM, 41
Ci/mmol, Novandi, Sweden) or [3H]C13 (3.5 nM, 13 Ci mmol−1, Novandi, Swe-
den) with or without increasing amounts of the indicated cold ligands (Tocris
(clozapine, C21) or custom synthesis). Slides were air dried and placed in a
Hypercassette™ (Amersham Biosciences) and covered with a BAS-TR2025 Storage
Phosphor Screen (FujiFilm, Japan). The slides were exposed to the screen for
5–7 days and imaged using a phosphor imager (Typhoon FLA 7000; GE
Healthcare).
[35S]GTPγS autoradiography. Flash frozen tissue was sectioned (10 µm) on a
cryostat (Leica) and thaw mounted on ethanol cleaned glass slides. Sections were
encircled with a hydrophobic membrane using a PAP pen (Sigma-Aldrich). Pre-
incubation buffer was pipetted onto each slide and allowed to incubate for 20 min
(50 mM Tris-HCl, 1 mM EDTA, 5 mM MgCl2 and 100 mM NaCl). The pre-
incubation buffer was removed via aspiration and each slide was loaded with GDP
in the presence of DPCPX and allowed to incubate of 60 min (Preincubation buffer,
2 mM GDP, 1 μM DPCPX, Millipore water). GDP buffer was removed via
aspiration and [35S]GTPγS cocktail (GDP buffer, 1.3 mM DTT, 2.7 mM GDP,
1.3 μM DPCPX, 83 pM [35S]GTPγS) with agonists of interest (C21 10 nM, clo-
zapine 10 nM), without agonists (basal condition), or with a saturated concentra-
tion of nonradioactive GTP (for nonspeciﬁc binding) was pipetted onto each slide
and allowed to incubate for 90 min. The [35S]GTPγS cocktail was removed via
aspiration and slides were washed in ice-cold washing buffer (50 mM Tris-HCl,
5 mM MgCl2, pH 7.4) for 5 min (2×) followed by a 30 s dip in ice-cold deionized
water. Hydrophobic membrane was removed with a cotton swab and xylene and
slides were placed into a Hypercassette™ covered by a BAS-SR2040 phosphor screen
(FujiFilm; GE Healthcare). The slides were exposed to the phosphor screen for
3–5 days and imaged using a phosphor imager (Typhoon FLA 7000; GE
Healthcare).
Binding and enzyme target proﬁle screen. These experiments were performed by
an outside vendor (Euroﬁns, France). Brieﬂy, membrane homogenates from stable
cell lines expressing each receptor/enzyme were incubated with the respective
radioligand in the absence or presence of clozapine or C21 or reference control
compounds in a buffer. In each experiment, the respective reference compound
was tested concurrently with the test compound to assess the assay reliability.
Nonspeciﬁc binding was determined in the presence of a speciﬁc agonist or
antagonist at the target. Following incubation, the samples were ﬁltered rapidly
under vacuum through glass ﬁber ﬁlters presoaked in a buffer and rinsed several
times with an ice-cold buffer using a 48-sample or 96-sample cell harvester. The
ﬁlters were counted for radioactivity in a scintillation counter using a scintillation
cocktail.
P-glycoprotein (P-gp) substrate assay. These experiments were performed by an
outside vendor (Euroﬁns, France). C21 was tested in P-gp substrate assessment
assays at 10 µM. The A to B and B to A permeability was measured in Caco-2 cells
in the presence and absence of verapamil, a P-gp inhibitor. Efﬂux ratios (E) were
calculated based on the apparent B–A and A–B permeability with and without
verapamil. In each experiment, the respective reference compound was tested
concurrently with the test compound to assess the assay reliability. Fluorescein was
used as the cell monolayer integrity marker. Fluorescein permeability assessment
(in the A–B direction at pH 7.4 on both sides) was performed after the permeability
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assay for the test compound. The cell monolayer that had a ﬂuorescein perme-
ability of less than 1.5 × 10−6 cm s−1 for Caco-2 was considered intact, and the
permeability result of the test compound from intact cell monolayer was reported.
Bioanalytical methods. Monkey blood and CSF samples were collected from
totally implanted subcutaneous access ports (Access Technologies, Virginia),
connected to catheters indwelling in the femoral artery or intrathecal space of the
spinal column, respectively. Rodent blood samples and brains were collected
immediately following sacriﬁce at the indicated time points after intraperitoneal
injection (10 ml kg−1) in buffered saline. CSF was immediately frozen on dry ice
and stored at −80 °C. Blood samples were allowed to coagulate for 15 min and then
centrifuged at 4 °C for 15 min. Serum was collected from the supernatant and
stored at a minimum of −30 °C until extraction. To 25 µl of serum, 5 µl of internal
standard and 110 µl of methanol were added. Samples were centrifuged for 10 min
at 16,200×g at 4 °C and the supernatant was transferred to the autosampler vial for
analysis. Brains were cut in half and weighed prior to sample preparation. Half
brains were homogenized in 490 µl of 85% ethanol: 15% water containing 0.1%
formic acid and 5 µl of internal standard using a polytron homogenizer and cen-
trifuged for 10 min at 16,200×g at 4 oC. A 300 µl of supernatant was dried under a
stream of nitrogen and resuspended in 150 µl methanol. The resuspended solution
was then centrifuged and 100 µl of supernatant was transferred to the autosampler
vial for analysis.
Data were acquired using a Nexera XR HPLC (Shimadzu) coupled with a
QTRAP 6500 (SCIEX), and was analyzed with Analyst 1.6 (SCIEX). The positive-
ion mode data were obtained using multiple reaction monitoring (MRM). The
instrumental source setting for curtain gas, ion spray voltage, temperature, ion
source gas 1, and ion source gas 2 were 30 psi, 5500 V, 500 C, 650 psi, and 5560 psi,
respectively. The collision activated dissociation was set to medium and the
entrance potential was 10 V. C21 was monitored using the MRM ion transition
(278.80→ 166.10) with declustering potentials (DP)= 90 V, collision cell exit
potentials (CXP)= 10 V and collision energies (CE)= 50 V. JHU37160 and
JHU37152 were monitored using the MRM ion transitions (359.10→ 288.10) with
DP= 70 V, CXP= 8 V and CE= 28 V. Clozapine was monitored using the
MRM ion transitions (327.30→ 270.10) with DP= 100 V; 80 V, CXP= 11 V and
CE= 40 V.
Separation of the C21, JHU37160, JHU37152, and clozapine was accomplished
using a C18 Security guard cartridge (4.6 × 4 mm) and an Eclipse XDB-C18
column (4.6 × 250 mm, 5 µm, Agilent) at 35 °C. Mobile phase A consisted of water
containing 0.1% formic acid and mobile phase B was methanol containing 0.1%
formic acid. The following linear gradient was run for 21.0 min at a ﬂow rate of
0.4 ml min−1: 0–2.00 min 20% B, 7.0 min 80% B, 12 min 90% B, 18.0 min 90% B,
18.1 min 20% B. Twelve-point calibration curves were prepared in standard
solution by a 0.5 serial dilution of standards from 0.92 µg ml−1 for C21; 1 µg ml−1
for JHU37160; and 0.2 µg/ml for JHU37152 and 0.4 µg ml−1 for clozapine. The
injection volume per sample was 10 μl. Samples were kept at 4 °C in the
autosampler tray prior to injection.
The data were measured using standard curves and quality controls, but it was
not validated to ICH guidelines. The concentrations of C21, JHU37160, and
JHU37152 was measured using area ratios calculated with the internal standard
clozapine (5 µl of 100 µg ml−1) and the concentrations of clozapine was measured
using area ratios calculated with JHU37160 as the internal standard (5 µl of
50 µg ml−1). Quality control standards (low, middle and high) were prepared by
adding the spiking standard to solution to 25 μl of serum and/or a half-brain and
relative values are reported.
Adeno-associated virus (AAV) injections in rodents. Animals were anesthetized
with isoﬂurane or a mix of ketamine/xylazine and prepped on a stereotaxic
apparatus (Kopf, Germany). The following AAVs expressing hM4Di or hM3Dq
fused to mCherry (or EGFP as a control) under the control of a hSyn promoter
were used when indicated: hSyn-hM4D(Gi)-mCherry (Addgene: 50475-AAV8),
hSyn-hM3D(Gq)-mCherry (Addgene: 50474-AAV8), hSyn-DIO-hM3D(Gq)-
mCherry (Addgene: 44361-AAV8), and hSyn-EGFP (Addgene: 50465-AAV8).
Based on corresponding mouse and rat brain atlases (Paxinos and Watson), the
following coordinates were used to target: the dorsal striatum: Mouse—AP= 1.00,
ML= ±1.50, DV=−3.55; Rat—AP= 1.70, ML= ±2.50, DV=−5.50, rat cortex:
AP= 1.70, ML= ±2.50, DV=−3.50, Rat VTA: AP=−5.5, ML= ± 0.8, DV=
−8.2. In all cases 1 µl/side was injected and all injections were performed using a
Hamilton Neuros 33G syringes at a ﬂow rate of 50 nl min−1, except for the
injections targeting the rat VTA, that were injected with a picospritzer over 90 s.
Lentivirus injections in monkeys. Surgical procedures were performed in a
veterinary operating facility under aseptic conditions. Vital signs were monitored
throughout the procedure. A pre-operative T1-weighted magnetic resonanace
imaging (MRI) for each monkey was used to determine the stereotaxic coordinates
for the sites of the lentivirus injection in the right amygdala. The skull region above
the target site was exposed by retracting the skin, fascia, and muscle in anatomical
layers. A small region of cranial tissue was then removed (~1.5 cm diameter) to
access the dura mater, into which incisions were made to provide access for the
infusion apparatus.
Lentivirus expressing an hM4Di-CFP fusion protein under an hSyn promoter11
with a titer of >109 infectious particles was loaded into a 100 µL glass syringe
(Hamilton Co., MA). The 31-gauge needle of the syringe was sheathed with a silica
capillary (450 µm OD) to create a step 1 mm from the base of the aperture. The
syringe was mounted in a Nanomite pump (Harvard Apparatus, Cambridge, MA).
The needle was lowered through the incision in the dura mater to each of the pre-
calculated target sites and 10 or 20 µL was infused at a rate of 1 µL min−1. Each
monkey received a total of between 10 and 12 injections (for a total injection
volume of 120–240 µL). Post-infusion, the needle was left in situ for 10 min after
each injection to allow pressure from the infusate to dissipate. The needle was then
slowly removed. At the completion of the injection series the soft tissues were
sutured together in anatomical layers.
Immunohistochemistry. Rodents were anesthetized with a ketamine and xylazine
mixture and transcardially perfused with PBS followed by 4% paraformaldehyde
(PFA). The brains were post-ﬁxed in 4% PFA (overnight, 4 °C) and then placed in
30% sucrose for 3–4 days. The brains were frozen and sectioned on a cryostat (40
µm) and collected in PBS with 0.1% Tween-20 (washing buffer). Slices were
blocked with bovine serum albumin 3% in washing buffer (blocking buffer, 2 h
RT), and incubated the primary antibody mixture: chicken anti-GFP (1:400,
ab13970, Abcam Inc.) and rabbit anti-HA (1:400, C29F4, Cell Signaling Tech-
nologies) overnight at 4 °C. Sections were washed in washing buffer (3 × 10 min,
RT) and incubated with the secondary antibody mix: Alexa488-conjugated goat
anti-rabbit (1:200, A11034, Invitrogen) and Alexa546-conjugated goat anti-chicken
(1:400, A11040, Invitrogen) and To-Pro3 iodide (Invitrogen) as a nuclear coun-
terstain. After washing (3 × 10 min in washing buffer and 1 × 5min in PBS) slices
were mounted on glass slides. Alternatively, ﬂash frozen tissue was sectioned (20
µm) on a cryostat (Leica) and mounted on ethanol-soaked glass slides. Sections
were ﬁxed with PFA (4%, 10 min at RT), permeabilized with PBS with TritonX-100
(0.1%, washing buffer), blocked with bovine serum albumin 5% in washing buffer
(2 h, RT), and then incubated overnight at 4 °C with the primary antibodies
mixture: rabbit anti-mCherry (1:500, ab167453, Abcam Inc.) and chicken anti-GFP
(1:2000, ab13970, Abcam Inc.). Sections were then washed again and incubated
with Alexa 647 goat anti-rabbit (1:200, A21245, Invitrogen) and Alexa 488 goat
anti-chicken (1:400, A11039, Invitrogen) and washed again. In both cases, sections
were coverslipped using mounting medium (ProLong Diamond antifade moun-
tant, Invitrogen), and images were acquired either using a confocal microscope
(Examiner Z1, Zeiss, Germany) with a laser scanning module (LSM-710, Zeiss,
Germany) or a Leica Zoom.V16 stereo microscope (Leica, Germany).
Synthesis of [11C]clozapine and [18F]JHU37107. [11C]clozapine was synthesized
using the methods developed by Bender et al.17 with minor modiﬁcations. Brieﬂy,
1 mg of N-desmethylclozapine was dissolved in 200 µL of acetonitrile. [11C]Methyl
triﬂate was bubbled into the solution until the radioactivity reached a plateau. The
reaction was kept at room temperature for 2 min. The solution was then diluted
with 200 µL of 40:60 (v:v) acetonitrile:water (0.1% ammonium hydroxide) and
injected onto semi-preparative HPLC. The column (Waters XBridge C18 10 mm ×
150 mm) was eluted with 40:60 (v:v) acetonitrile:water (0.1% ammonium hydro-
xide) at a ﬂow rate of 10 mLmin−1. The radioactive peak corresponding to [11C]
clozapine (tR= 6.1 min) was collected in a reservoir containing 50 mL of water and
250 mg of L-ascorbic acid. The diluted product was loaded onto a solid phase
extraction cartridge (Waters Oasis HLB plus light) and rinsed with 3.0 mL of water.
The product was eluted with 400 µL of ethanol into a sterile, pyrogen-free bottle
and diluted with 4.0 mL of saline. A 10 µL aliquot of the ﬁnal product was injected
onto an analytical high-performance liquid chromatography (HPLC) column
(Waters XBridge C18 4.6 mm × 100 mm) and eluted with 35:65 (v:v) acetonitrile:
water (0.1% ammonium hydroxide) at a ﬂow rate of 2 mLmin−1. The radioactive
peak corresponding to [11C]clozapine (tR= 9.2 min) coeluted with a standard
sample. The semi-preparative HPLC eluant used was 25:75 (v:v) acetonitrile:water
(0.1% ammonium hydroxide), and no ascorbic acid was added to the reservoir. The
molar activity for both [11C]clozapine ranged from 351 to 483 GBq µmol−1
(9482–13,041 mCi µmol−1) at end of synthesis.
[18F]JHU37107 was prepared via the no-carrier-added 18F-ﬂuorination using an
FDG Nuclear Interface module (Muenster, Germany). Brieﬂy, 4 mg precursor (8-
chloro-11-(4-ethylpiperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepin-2-ol) and 8 mg
tris(acetonitrile)cyclopentadienylruthenium(II)hexaﬂuorophosphate (STREM,
Boston, MA) were dissolved in ethanol (0.3 mL), the solution was heated at 85 °C
for 25 min and evaporated to dryness under a stream of argon gas. The residue was
dissolved in DMSO (0.5 mL) and acetonitrile (0.5 mL) and the solution was added
to a dry complex of [18F]ﬂuoride and 9 mg 1,3-bis(2,6-di-i-propylphenyl)-2-
chloroimidazolium chloride (STREM). The reaction mixture was heated at 130 oC
for 30 min, diluted with mixture of 0.5 mL acetonitrile, 0.5 mL water and 0.03 mL
TFA and injected onto a semi-preparative HPLC column (Luna C18, 10 micron,
10 mm × 250 mm) and eluted with 23:77 (v:v) acetonitrile:water (0.1%
triﬂuoroacetic acid) at a ﬂow rate of 10 mLmin−1. The radioactive peak
corresponding to [18F]JHU37107 (tR= 9.9 min) was collected in a reservoir
containing 50 mL of water and 3 mL aq 8.4% NaHCO3 solution. The diluted
product was loaded onto a solid phase extraction cartridge (Waters Oasis HLB plus
light) and rinsed with 10 mL sterile saline. The product was eluted with 1000 µL of
ethanol through a sterile 0.2 μm ﬁlter into a sterile, pyrogen-free vial and 10 mL
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saline was added through the same ﬁlter. The ﬁnal product [18F]JHU37107 was
then analyzed by analytical HPLC (Luna C18, 10 micron, 4.6 mm × 250mm;
mobile phase 23:77 (v:v) acetonitrile:water (0.1% triﬂuoroacetic acid), ﬂow rate of
3 mLmin−1; tR= 6.4 min) using a UV detector at 254 nm to determine the
radiochemical purity (>95%) and speciﬁc radioactivity (152–188 GBq μmol−1
(4100–5070 mCi μmol−1)) at the time synthesis ended.
[11C]clozapine and [18F]JHU37107 imaging using PET. Mice and rats were
anesthetized with isoﬂurane and placed in a prone position on the scanner bed of
an ARGUS small animal PET/CT (Sedecal, Spain) or a nanoScan PET/CT (Mediso,
USA) injected intravenously (~100–200 µL) with [11C]clozapine (~700 μCi) or
[18F]JHU37107 (~350 μCi) and dynamic scanning commenced. When indicated,
animals were pretreated with vehicle or the indicated drug 10 min before the
injection of the PET radiotracer. Total acquisition time was 60 min.
All macaque studies were acquired dynamically on the Focus 220 PET scanner
(Siemens Medical Solutions, Knoxville, TN). The Focus 220 is a dedicated pre-
clinical scanner with a transaxial FOV of 19 cm and an axial FOV of 7.5 cm. Image
resolution is <2 mm within the central 5 cm FOV.
After initial evaluation the monkey was sedated with ketamine (10 mg kg−1)
followed by ketoprofen (as an analgesic) and glycopyrrolate (for salvia reduction),
all weight dependent IM injections. The monkey would then be placed in the
supine position, intubated with a tracheal tube. Anesthesia was maintained by
1–3.5% isoﬂurane and oxygen, the monkey’s head was positioned and immobilized
for optimal positioning of the brain and moved into the scanner. A 10-min
transmission scan using a Co-57-point source for attenuation correction was
performed. One iv was inserted, if possible, in the right arm and one in the right leg
for injection of tracer and blocking agent. The monkey was always monitored while
anesthetized. HR, BP, O2 saturation, RR, three lead ECG, rectal temperature was
documented every 15 min.
Arterial blood sampling was acquired throughout the study using an indwelling
femoral port. The ﬁrst 2 min samples were collected every 15 s then at 3, 5, 10, 30,
60, 90, and 120 min post tracer injection. All scans were acquired for 120 min using
list mode acquisition.
Scan data were histogrammed into 33 frames (6 × 30 s, 3 × 1 min, 2 × 2 min, and
22 × 5min). Reconstruction was performed by Filtered Back Projection with scatter
correction. After completion of the last study of the day, isoﬂurane was cut off. The
monkey was gradually awakened, moved to the housing facility and fully recovered.
In all cases, the PET data were reconstructed and corrected for dead-time and
radioactive decay. All qualitative and quantitative assessments of PET images were
performed using the PMOD software environment (PMOD Technologies, Zurich
Switzerland). Binding potential BPND (a relative measure of speciﬁc binding) was
calculated using a reference tissue model using the cerebellum as a reference tissue
in rodents. In macaques, the kinetic data were ﬁtted to a two-tissue compartment
model and the concentration of parent in plasma was used as an input function,
then the volume of distribution ratios compared to cerebellum were calculated to
establish BPND. In all cases, the dynamic PET images were coregistered to MRI
templates and time-activity curves were generated using predeﬁned volumes of
interest (macaques) or manually drawn in rodents and the described analyses were
performed. Receptor occupancy was calculated using the formula: occupancy=
(BPND0− BPNDDrug)/BPND0 × 100, where BPND0 is the binding potential of the
baseline condition and BPNDDrug the binding potential when the animals were
pretreated with the drug. In an independent manner, BPND parametric maps were
generated by pixel-based kinetic modeling using a multilinear reference tissue
model18 using the cerebellum as a reference region and the start time (t*) was set to
16 min.
To determine the arterial input function for the radiotracers injected in rhesus
monkeys radioligand concentrations in the arterial plasma were corrected by the
unchanged parent fraction. Heparinized blood samples (0.5 mL each) were drawn
at 15-s intervals until 2 min, and at 3, 5, 10, and 30 min followed by 3-mL samples
at 60, 90, 120 min ([11C]clozapine) and 150, 180 min ([18F]JHU37107). Blood
samples were immediately sampled for gamma counting, and plasma harvested by
centrifugation for gamma counting and radio-HPLC analysis. The unchanged
plasma parent fractions were determined by radio-HPLC on an X-terra® C18
column (10 µm, 7.8 mm × 300 mm, Waters Corp., Milford, MA), and eluted with
MeOH:H2O:Et3N (80:20:0.1; by volume) at an isocratic ﬂow rate of 4.0 mLmin−1.
Eluates were monitored with an in-line ﬂow-through NaI(Tl) scintillation detector
(Bioscan). Data were stored and analyzed on a PC using the software “Bio-
ChromeLite”. The collection of data for each radiochromatogram was decay
corrected according to its respective HPLC injection time. Plasma free fraction was
determined according to our previous methods19.
DREADD-assisted metabolic mapping (DREAMM). Mice (D1-hM3Dq, D1-
hM4Di or WT littermates, see above) were habituated to experimenter handling
and fasted 16 h before the experiment. On the day of the experiment, mice received
an IP injection of vehicle (1 ml kg−1) and were placed back into their home cages.
Ten minutes later, mice were injected (IP) with 11 MBq of 2-deoxy-2-[18F]ﬂuoro-
D-glucose (FDG, Cardinal Health) and placed back into their home cages. After 30
min, mice were anesthetized with 1.5% isoﬂurane, placed on a custom-made bed of
a nanoScan small animal PET/CT scanner (Mediso Medical Imaging Systems) and
scanned for 20 min on a static acquisition protocol, followed by a CT scan. One
week later the animals were fasted overnight, the next day received an IP injection
of C21 (1 mg kg−1), clozapine (0.1 mg kg−1), or JHU37160 (0.1 mg kg−1), and the
FDG-PET procedure was conducted as described above. In all cases, the PET data
were reconstructed and coregistered to an MRI template as described above. Voxel-
based repeated measures with Student’s t test comparing baseline to drug were
performed, and the resulting parametric images were ﬁltered for statistically sig-
niﬁcant (p < 0.05) clusters larger than 100 contiguous voxels. All statistical para-
metric mapping analyses were performed using Matlab R2016 (Mathworks) and
SPM12 (University College London).
[3H]clozapine, [3H]C21 and [3H]C13 biodistribution and uptake. Mice were
injected (IP) with [3H]clozapine, [3H]C21, or [3H]C13 (2 µCi g−1), euthanized 30
min later and brain, blood, and tissues were collected for radiometric analyses. The
brains were ﬂash frozen in isopentane (Sigma-Aldrich) and stored at −80 °C until
use. The blood was centrifuged (13,000 rpm, 10 min at RT) and serum was col-
lected. The tissues were solubilized with SolvableTM (PerkinElmer) and bleached
with hydrogen peroxide (Sigma-Aldrich). Serum and tissue samples were dissolved
in scintillation cocktail and radioactivity counts were determined in a Beckman LS
60000TA scintillation counter (BeckmanCoulter, Indianapolis, IN, USA). Samples
were not further analyzed to verify that the tritium signal corresponds to the parent
compound so some radiometabolites might contribute to the signal detected in
some organs.
Locomotor activity assessment in mice. Transgenic male and female mice (see
above) (20–30 g) expressing hM3Dq or hM4Di and mCitrine reporters (or con-
trols) were tested for locomotor activity. Mice were injected (IP) with the indicated
dose of clozapine, C21, JHU37152 or JHU37160 or vehicle (buffered saline). Ten
minutes after injection, animals were placed in an open ﬁeld arena (Opto-varimex
ATM3, Columbus Instruments) and their locomotor activity was tracked during
60 min as infrared beam crossings and traveled distance was converted to cm.
Animals were repeatedly tested on consecutive sessions (after an initial habituation
session with no drug treatment) in a counterbalanced design.
Locomotor activity assessment in rats. Tyrosine hydroxylase (TH):Cre rats (n=
9; founder, K. Deisseroth lab) or WT littermates (n= 9) were bilaterally injected
with AAV2 hSyn-DIO-hM3Dq-mCherry (1ul/hemisphere, Addgene), and allowed
to recover for 2+weeks. Following handling, they were habituated to a Med
Associates locomotor testing box (43 × 43 × 30.5 cm) for 2 h on 2 days, then
repeatedly tested after separate day doses of DREADD agonists and vehicle. Cohort
one was administered C21 (1 or 5 mg kg−1) or clozapine (0.001–0.5 mg kg−1), and
vehicle, in counterbalanced order on separate days, with each test separated by at
least 48 h. The 2 h locomotor testing session commenced 30 min after each IP
injection on each day. Vehicle was administered on 2 separate days, and average
locomotion was used for comparison with DREADD agonists. Cohort 2 underwent
the same procedures, but with a 4 h testing session, and the following IP injections:
vehicle (x2), JHU37152 (0.01–0.3 mg kg−1), JHU37160 (0.01–0.3 mg kg−1). All
drugs were dissolved in 5% DMSO in saline, and injected 1 ml kg−1. Following all
tests, rats were transcardially perfused, brains sectioned coronally at 40 µm, and
VTA-speciﬁc expression conﬁrmed using endogenous mCherry reporter expres-
sion, which co-localized nearly exclusively with TH immunoreactivity.
ChrimsonR generation and characterization. pcDNA3.1(+)/Hygro vector (Life
Technologies, Carlsbad, CA, USA) was used for expression of Chrimson, oC-
Chrimson and oC-Chrimson-ts in HEK293A cells (Life Technologies, Carlsbad,
CA, USA). Channelrhodopsin inserts (with and without modiﬁcation) were cloned
into the BamHI and XhoI site and the ﬂuorescent protein (tdTomato or citrine)
was cloned in-frame and a 3′ stop codon between the XhoI and XbaI site. For
neuron expression, the channelrhodopsin-FP inserts were placed in an AAV2
vector between BamHI and HindIII sites (Addgene #50954). Transfection in
HEK293 cells were achieved with Fugene (Roche, Basel, Switzerland) and elec-
troporation (Lonza, Gaithersburg, MD, USA) was used for expression in neuronal
culture. HEK293 cell experiments were performed 2 days post transfection,
whereas neuronal experiments were performed >10 days post transfection. Cell
culture conditions were as described previously20.
For visualizing the channelrhodopsin-FP expression, images were taken on a
Zeiss Axiovert 200M microscope (Zeiss, Jena, Germany) with Slidebook software
(3i, Denver, CO, USA) using a Cascade II 1024 EMCCD camera (Photometrics,
Tucson, AZ, USA). Images were taken with a 40× oil objective with NA of 1.2.
Citrine images were acquired with 495/10 excitation ﬁlter and 535/25 nm ﬁlters
and tdTomato images were acquired with 580/20 nm excitation and 653/95 nm
emission ﬁlters (Semrock, Rochester, NY, USA). For analyzing membrane/cytosolic
ﬂuorescence, a line proﬁle was drawn across the cell in ImageJ or Fiji, the
ﬂuorescence intensity of the two membrane regions and cytosolic portion
(including nucleus) were measured from proﬁle. After background subtraction, the
mean membrane and mean cytosolic ﬂuorescence were calculated and the ratio was
calculated.
Electrophysiological recording was performed with an extracellular solution
containing 118 mM NaCl, 3 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM 4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 20 mM glucose (pH
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7.35, 310 mOsm), and an intracellular solution containing 110 mM Cs-
methanesulfonate, 30 mM tetraethylammonium chloride, 10 mM ethylene glycol
tetraacetic acid (EGTA), 10 mM HEPES, 1 mM CaCl2, 1 mM MgCl2, 2 mM Mg-
ATP and 0.15 mM Na3-GTP (pH 7.25, 285 mOsm). All chemicals were acquired
from Sigma-Aldrich (St. Louis, MO). Due to the desensitization of the Chrimson
response to high intensity of light to some wavelengths, a 1 s 410 nm conditioning
light was used to illuminate the recorded cell 10 s prior to testing with indicated
wavelength of light.
In vivo electrophysiology. Mice were purchased from Janvier Labs and stored in
grouped cages (maximun 4 per cage) with ad libitum access to food and water, and
in a 12 h light/dark cycle (lights on at 7:00 a.m.). All the experiments were per-
formed in accordance to the national Danish law for the use of laboratory animals
and approved by local authorities.
For AAV injection, mice were anaesthetized with Isoﬂurane and placed in a
stereotaxic holder (Narishige, Japan). A trephine hole was drilled above the MGM
(from bregma, AP 3.1 mm, ML 1.8 mm). Several injections of a mixture of ssAAV-
8/2-hSyn1-hM4D(Gi)_mCherry-WPRE-hGHp(A) and ssAAV-8/2-hSyn1-
oChIEF_ChrimsonR_mCitrine-WPRE-SV40pA (in a 1:4 viral particle ratio) were
performed sequentially in different locations (AP 3.05 mm, ML 1.75 mm, DV 3.2
and 3.5 mm; second location AP 3.2 mm, ML 1.85 mm, DV 3.3 and 3.6 mm) so
that a total of 4 injections of 0.5 µL were made to distribute the virus evenly
through the desired location. Injections were made using a pressurized picospritzer
and a pulled glass pipette. After viral injection, animals were kept for 4 weeks to
ensure maximum virus expression through axon terminals.
For recording experiments, animals were anesthetized with 1.8 mg kg−1
urethane (i.p.), injected with 0.1 ml lidocaine (s.c.) in the incision points, and
placed in a stereotaxic holder (Narishige, Japan). A trephine was drilled above the
LA (from bregma, AP 1.5 mm, ML 3.1 mm) and the 32 channel opto-electrode was
lowered whilst stimulating until a maximum response was located (DV 4 ±
0.2 mm). Body temperature was maintained constant at 37 °C through a feedback-
regulated heating pad. Before recording, tissue was left for 10–20 mins for
accommodation. Input–output test curves were recorded for both intensity and
pulse length 30 min before and 1 h after drug injections using 1 ms-long pulses at
0.33 Hz (450 nm, 110 mA light intensity, ~14 mW, see Supplementary Fig. 10 Panel
A). For electrical stimulation experiments (see Supplementary Fig. 10, Panels F–H),
a stimulation bipolar twisted platinum–iridium microelectrode was placed in the
internal capsule (AP −1.7 mm, ML 2.5 mm, DV 4.0 mm) to target the axons
innervating the amygdala. Electrical pulses were given at an intensity that evoked
80% of the maximum response as biphasic 100 µs long pulses at 0.33 Hz.
Raw data were ﬁltered (0.1–3000 Hz), ampliﬁed (100×), digitized and stored
(10 kHz sampling rate) for ofﬂine analysis, with a tethered recording system
(Multichannel Systems, Reutlingen, Germany). Analysis was performed using
custom routines. After completion of the experiment, animals were sacriﬁced by
decapitation and brains were extracted and kept in 4% PFA overnight (RT). Brains
were then sliced (50 µm) and inspected for viral infection location, extent, and
electrode placement.
Molecular modeling. The crystal structure of human muscarinic M4 receptor
[Protein Data Bank (PDB) code: 5DSG] was used (after removing the bound
ligand, tiotropium) for our modeling study. We made the Y1133.33G and
A2035.56G in the M4 structure to create a DREADD (hM4Di). JHU37160 was
prepared using LigPrep (Schrodinger LLC: New York, NY, 2017). The pKa calcu-
lations using Epik from Schrodinger suite (release 2017–4) and Chemicalize pre-
dicted that the piperazine nitrogen closer to the ethyl moiety has pKa values of
7.4–7.5 and we therefore protonated that nitrogen. Docking was performed using
induced-ﬁt docking protocol21 (Schrodinger LLC, New York, NY, 2017) with the
OPLS3 force ﬁeld. Four largest docking clusters with various orientations of the
dibenzodiazepine moiety in the ligand binding site were identiﬁed using Clustering
of Conformers in Maestro. The poses with the lowest docking scores from each of
these four clusters were chosen for further MD simulations. Desmond MD systems
(D. E. Shaw Research, New York, NY) with OPLS3 force ﬁeld was used for the MD
simulations. hM4Di was placed into explicit 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine lipid bilayer using the orientation of the 5DSG structure from the
Orientation of Proteins in Membranes database. Simple point charge water model
was used to solvate the system, charges were neutralized, and 0.15M NaCl was
added. The total system size was ∼96000 atoms. The NPγT ensemble was used with
constant temperature (310 K) maintained with Langevin dynamics, 1 atm constant
pressure achieved with the hybrid Nose-Hoover Langevin piston method on an
anisotropic ﬂexible periodic cell, and a constant surface tension (x–y plane). The
system was initially minimized and equilibrated with restraints on the ligand heavy
atoms and protein backbone atoms, followed by production runs at 310 K with all
atoms unrestrained. Two independent trajectories for each of the four JHU37160
poses were collected with an aggregated simulation length of 10.56 μs. Only one of
the four poses both retained its ionic interaction with Asp1123.32 and showed
convergence between the two trajectories, and thus was chosen for our further
analysis shown in Fig. 3m.
Statistics. Sample sizes were chosen based on our results from previous experi-
ments. Depending on experiment, we used paired/two-sample t tests or single
factor and multifactor ANOVAs with Dunnett’s or Tukey post hoc tests, taking
repeated measures into account where appropriate. All statistical tests were eval-
uated at the P ≤ 0.05 level.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The source data underlying the ﬁgures are provided as a Source Data ﬁle or can be
obtained from the authors upon request.
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